Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
27T51 CAR T cell therapy in recurrent/refractory ovarian cancer
NCT06469281Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- May 2030
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of 27T51 in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at 18 months, Adverse Events of Special Interest at 18 months and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
27T51
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06469281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469281.